Intra-Cellular Therapies (NASDAQ:ITCI) and IDEAYA Biosciences (NASDAQ:IDYA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.
Insider & Institutional Ownership
79.1% of Intra-Cellular Therapies shares are held by institutional investors. Comparatively, 62.3% of IDEAYA Biosciences shares are held by institutional investors. 18.2% of Intra-Cellular Therapies shares are held by company insiders. Comparatively, 20.7% of IDEAYA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares Intra-Cellular Therapies and IDEAYA Biosciences' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| Intra-Cellular Therapies | -1,985.32% | -48.27% | -42.56% |
| IDEAYA Biosciences | N/A | -28.83% | -22.92% |
Valuation & Earnings
This table compares Intra-Cellular Therapies and IDEAYA Biosciences' gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| Intra-Cellular Therapies | $60,000.00 | 41,024.92 | $-147,720,000.00 | ($2.68) | -11.35 |
| IDEAYA Biosciences | N/A | N/A | $-41,970,000.00 | ($3.36) | -5.82 |
IDEAYA Biosciences has lower revenue, but higher earnings than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Intra-Cellular Therapies and IDEAYA Biosciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| Intra-Cellular Therapies | 0 | 0 | 7 | 0 | 3.00 |
| IDEAYA Biosciences | 0 | 0 | 7 | 0 | 3.00 |
Intra-Cellular Therapies currently has a consensus target price of $47.4286, indicating a potential upside of 55.91%. IDEAYA Biosciences has a consensus target price of $32.2222, indicating a potential upside of 64.82%. Given IDEAYA Biosciences' higher probable upside, analysts clearly believe IDEAYA Biosciences is more favorable than Intra-Cellular Therapies.
Volatility & Risk
Intra-Cellular Therapies has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Comparatively, IDEAYA Biosciences has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500.
Summary
IDEAYA Biosciences beats Intra-Cellular Therapies on 7 of the 11 factors compared between the two stocks.
